Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers

Future Oncology

Volumn 7, Issue 12, 2011, Pages 1415-1428

  Singh, Brahma N ^a   Zhou, Hongyuan ^b   Li, Jinping ^a   Tipton, Tracy ^c   Wang, Bin ^d   Shao, Guo ^a   Gilbert, E Nickolas ^e   Li, Qiang ^b   Jiang, Shi Wen ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^e MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chemotherapy; gynecologic cancer; HDAC; HDAC inhibitor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ACETYLSALICYLIC ACID; APICIDIN; BELINOSTAT; BUTYRIC ACID; CARBOPLATIN; CL 958; DACINOSTAT; DOCETAXEL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; M 344; MESSENGER RNA; OXAMFLATIN; PACLITAXEL; PANOBINOSTAT; R 306465; R 306565; ROMIDEPSIN; SULFORAPHANE; TACEDINALINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CELL CYCLE PROGRESSION; DEACETYLATION; ENDOMETRIUM CANCER; HUMAN; LEUKEMIA; MELANOMA; MULTIPLE MYELOMA; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UTERINE TUBE CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; OVARIAN NEOPLASMS;

EID: 82455162313     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.124     Document Type: Review

References (114)

1. Khan N, Jeffers M, Kumar S et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409(2), 581-589 (2008).
2. Cang S, Ma Y, Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol. 2, 22 (2009).
3. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007).
4. Smith BC, Hallows WC, Denu JM. Mechanisms and molecular probes of sirtuins. Chem. Biol. 15(10), 1002-1013 (2008).
5. Spange S, Wagner T, Heinzel T et al. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 41(1), 185-198 (2009).
6. Fullgrabe J, Kavanagh, E Joseph B. Histone onco-modifications. Oncogene 30(31), 3391-3403 (2011).
7. Sawan C, Herceg Z. Histone modifications and cancer. Adv. Genet. 70, 57-85 (2010).
8. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther. 8(6), 1409-1420 (2009).
9. Gallinari P, Di Marco S, Jones P et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 17(3), 195-211 (2007).
10. Buchwald M, Kramer OH, Heinzel T. HDACi - targets beyond chromatin. Cancer Lett. 280(2), 160-167 (2009).
11. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell Biochem. 107(4), 600-608 (2009).
12. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69(14), 1911-1934 (2009).
13. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 26(9), 1351-1356 (2007).
14. Jabbour E, Issa JP, Garcia-Manero G et al. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112(11), 2341-2351 (2008).
15. Berry E, Hardt JL, Clardy J et al. Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1. Gynecol. Oncol. 112(2), 331-336 (2009).
16. Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 23(7), 635-642 (2005).
17. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 25(26), 4051-4056 (2007).
18. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4(1), 13-18 (2003).
19. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459-5468 (2009).
20. Blagosklonny MV, Robey R, Sackett DL et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther. 1(11), 937-941 (2002).
21. Nishioka C, Ikezoe T, Yang J et al. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk. Res. 32(9), 1382-1392 (2008).
22. Lee JH, Choy ML, Ngo L et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl Acad. Sci. USA 107(33), 14639-14644 (2010).
23. Kauh J, Fan S, Xia M et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS ONE 5(4), E10376 (2010).
24. Yeh CC, Deng YT, Sha DY et al. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol. Cancer Ther. 8(9), 2718-2725 (2009).
25. Scott GK, Mattie MD, Berger CE et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66(3), 1277-1281 (2006).
26. Masuoka Y, Shindoh N, Inamura N. Histone deacetylase inhibitors from microorganisms: the Astellas experience. Prog. Drug Res. 66(335), 337-359 (2008).
27. Yu X, Guo ZS, Marcu MG et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94(7), 504-513 (2002).
28. INK4A RNA transcripts expressed in hepatocellular carcinoma cell lines regulate pRb phosphorylation by binding with CDK4, resulting in delayed cell cycle progression. Liver Int. 23(3), 194-200 (2003).
29. Leder A, Orkin S, Leder P. Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science 190(4217), 893-894 (1975).
30. Schneider-Stock R, Ocker M. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 10(8), 557-561 (2007).
31. Takai N, Desmond JC, Kumagai T et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 10(3), 1141-1149 (2004).
32. Vigushin DM, Ali S, Pace PE et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7(4), 971-976 (2001).
33. Kwon HJ, Owa T, Hassig CA et al. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl Acad. Sci. USA 95(7), 3356-3361 (1998).
34. Marks P, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nature Rev. 1(3), 194-202 (2001).
35. Zhou XC, Dowdy SC, Podratz KC et al. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol. Oncol. 107(1), 143-153 (2007).
36. Terao Y, Nishida J, Horiuchi S et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int. J. Cancer 94(2), 257-267 (2001).
37. Takai N, Kawamata N, Gui D et al. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101(12), 2760-2770 (2004).
38. Marzio G, Wagener C, Gutierrez MI et al. E2F family members are differentially regulated by reversible acetylation. J. Biol. Chem. 275(15), 10887-10892 (2000).
39. Ammanamanchi S, Freeman JW, Brattain MG. Acetylated SP3 is a transcriptional activator. J. Biol. Chem. 278(37), 35775-35780 (2003).
40. Mariadason JM, Velcich A, Wilson AJ et al. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology 120(4), 889-899 (2001).
41. Dowdy SC, Jiang S, Zhou XC et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther. 5(11), 2767-2776 (2006).
42. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92(15), 1210-1216 (2000).
43. Khabele D, Son DS, Parl AK et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol. Ther. 6(5), 795-801 (2007).
44. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280(2), 168-176 (2009).
45. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14(2), 121-141 (2000).
46. Wilson AJ, Byun DS, Popova N et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281(19), 13548-13558 (2006).
47. Ayer DE. Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell. Biol. 9(5), 193-198 (1999).
48. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol. Cell Biol. 25(8), 2873-2884 (2005).
49. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9(3), 206-218 (2008).
50. Weichert W, Denkert C, Noske A et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10(9), 1021-1027 (2008).
51. Krusche CA, Vloet AJ, Classen-Linke I et al. Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum. Reprod. 22(11), 2956-2966 (2007).
52. Kawai H, Li H, Avraham S et al. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int. J. Cancer 107(3), 353-358 (2003).
53. Zhu P, Martin E, Mengwasser J et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5(5), 455-463 (2004).
54. Rampalli S, Pavithra L, Bhatt A et al. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol. Cell Biol. 25(19), 8415-8429 (2005).
55. Jin KL, Pak JH, Park JY et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J. Gynecol. Oncol. 19(3), 185-190 (2008).
56. Shang Y, Hu X, DiRenzo J et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103(6), 843-852 (2000).
57. Liu XF, Bagchi MK. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J. Biol. Chem. 279(15), 15050-15058 (2004).
58. Hrzenjak A, Moinfar F, Kremser ML et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 5(9), 2203-2210 (2006).
59. Drummond DC, Noble CO, Kirpotin DB et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495-528 (2005).
60. Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 280(2), 134-144 (2009).
61. Qian DZ, Wang X, Kachhap SK et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 64(18), 6626-6634 (2004).
62. Deroanne CF, Bonjean K, Servotte S et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3), 427-436 (2002).
63. Michaelis M, Michaelis UR, Fleming I et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol. Pharmacol. 65(3), 520-527 (2004).
64. Sawa H, Murakami H, Ohshima Y et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. 19(2), 77-81 (2002).
65. Takai N, Ueda T, Nishida M et al. Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells. Int. J. Mol. Med. 21(1), 109-115 (2008).
66. Takai N, Narahara H. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr. Med. Chem. 14(24), 2548-2553 (2007).
67. Takai N, Ueda T, Nishida M et al. CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Oncology 70(2), 97-105 (2006).
68. Ueda T, Takai N, Nishida M et al. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int. J. Mol. Med. 19(2), 301-308 (2007).
69. Inoue K, Kobayashi M, Yano K et al. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler. Thromb. Vasc. Biol. 26(12), 2652-2659 (2006).
70. Pina IC, Gautschi JT, Wang GY et al. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 68(10), 3866-3873 (2003).
71. Ahn MY, Jung JH, Na YJ et al. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol. Oncol. 108(1), 27-33 (2008).
72. Tabudravu JN, Eijsink VG, Gooday GW et al. Psammaplin A, a chitinase inhibitor isolated from the Fijian marine sponge Aplysinella rhax. Bioorg. Med. Chem. 10(4), 1123-1128 (2002).
73. Huang H, Tindall DJ. FOXO factors: a matter of life and death. Future Oncol. 2(1), 83-89 (2006).
74. Myzak MC, Karplus PA, Chung FL et al. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 64(16), 5767-5774 (2004).
75. Myzak MC, Hardin K, Wang R et al. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 27(4), 811-819 (2006).
76. Jiang S, Dowdy SC, Meng XW et al. Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells Gynecol. Oncol. 105(2), 493-500 (2007).
77. Uchida H, Maruyama T, Ono M et al. Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 148(2), 896-902 (2007).
78. Seppala M, Taylor RN, Koistinen H et al. Glycodelin: a major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation. Endocr. Rev. 23(4), 401-430 (2002).
79. Mandelin E, Lassus H, Seppala M et al. Glycodelin in ovarian serous carcinoma: association with differentiation and survival. Cancer Res. 63(19), 6258-6264 (2003).
80. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl. 16), 15-18 (2002).
81. Folkman J. Angiogenesis and proteins of the hemostatic system. J. Thromb. Haemost. 1(8), 1681-1682 (2003).
82. Michaelis M, Suhan T, Reinisch A et al. Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition. Invest. Ophthalmol. Vis. Sci. 46(9), 3451-3457 (2005).
83. Qian DZ, Kato Y, Shabbeer S et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12(2), 634-642 (2006).
84. Kim MS, Kwon HJ, Lee YM et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7(4), 437-443 (2001).
85. Kwon HJ, Kim MS, Kim MJ et al. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 97(3), 290-296 (2002).
86. Teodoridis JM, Strathdee G Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist. Updat. 7(4-5), 267-278 (2004).
87. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer 45(7), 1129-1136 (2009).
88. Zhu WG, Lakshmanan RR, Beal MD et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61(4), 1327-1333 (2001).
89. Chobanian NH, Greenberg VL, Gass JM et al. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res. 24(2B), 539-545 (2004).
90. Ramondetta L, Burke TW, Levenback C et al. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol. Oncol. 82(1), 156-161 (2001).
91. Zanotti KM, Belinson JL, Kennedy AW et al. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 74(2), 272-277 (1999).
92. Sonnemann J, Gange J, Pilz S et al. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients/ BMC cancer 6, 183 (2006).
93. Cooper AL, Greenberg VL, Lancaster PS et al. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol. Oncol. 104(3), 596-601 (2007).
94. Plumb JA, Finn PW, Williams RJ et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2(8), 721-728 (2003).
95. Gimsing P, Hansen M, Knudsen LM et al. A Phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 81(3), 170-176 (2008).
96. Ramalingam SS, Belani CP, Ruel C et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J. Thorac. Oncol. 4(1), 97-101 (2009).
97. Sonnemann J, Huls I, Sigler M et al. Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. Oncol. Rep. 20(1), 219-224 (2008).
98. Zhang Y, Li N, Caron C et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22(5), 1168-1179 (2003).
99. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA 77(3), 1561-1565 (1980).
100. Uchida H, Maruyama T, Nagashima T et al. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 146(12), 5365-5373 (2005).
101. Modesitt SC, Sill M, Hoffman JS et al. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109(2), 182-186 (2008).
102. Arts J, Angibaud P, Marien A et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br. J. Cancer 97(10), 1344-1353 (2007).
103. Hoffman MA, Blessing JA Morgan M. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study. Gynecol. Oncol. 79(3), 463-465 (2000).
104. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 74(5), 659-671 (2007).
105. Steele NL, Plumb JA, Vidal L et al. A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14(3), 804-810 (2008).
106. Dallavalle S, Cincinelli R, Nannei R et al. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur. J. Med. Chem. 44(5), 1900-1912 (2009).
107. Takai N, Ueda T, Nishida M et al. M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol. Oncol. 101(1), 108-113 (2006).
108. Xiong Y, Dowdy SC, Podratz KC et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 65(7), 2684-2689 (2005).
109. National Cancer Institute NCI Drug Dictionary: romidepsin. www.cancer.gov/Templates/drugdictionary.aspx?Cdr42600 (Accessed 18 October 2011)
110. NIH clinical trial: FR901228 in Treating Patients with Metastatic Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT00098397 (Accessed 18 October 2011)
111. NIH clinical trial: FR901228 in Treating Patients with Relapsed or Refractory Advanced Ovarian Epithelial Cancer. http://clinicaltrials.gov/ct2/ show/NCT00085527 (Accessed 18 October 2011)
112. NIH clinical trial: FR901228 in Treating Patients with Unresectable Stage III or Stage IV Malignant Melanoma. http://clinicaltrials.gov/ct2/show/ NCT00104884 (Accessed 18 October 2011)
113. NIH clinical trial: FR901228 in Treating Patients with Locally Advanced or Metastatic Neuroendocrine Tumors. http://clinicaltrials.gov/ct2/show/ NCT00084461 (Accessed 18 October 2011)
114. NIH clinical trial: FR901228 in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia. http://clinicaltrials.gov/ct2/show/ NCT00062075 (Accessed 18 October 2011)